Coherus Oncology, Inc.CHRSNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank38
3Y CAGR-18.3%
5Y CAGR-5.3%
Year-over-Year Change
Research and development spending
3Y CAGR
-18.3%/yr
vs +16.0%/yr prior
5Y CAGR
-5.3%/yr
Recent deceleration
Acceleration
-34.2pp
Decelerating
Percentile
P38
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $108.89M | +16.7% |
| 2024 | $93.34M | -14.7% |
| 2023 | $109.44M | -45.1% |
| 2022 | $199.36M | -45.1% |
| 2021 | $363.11M | +154.3% |
| 2020 | $142.76M | +51.6% |
| 2019 | $94.19M | -14.6% |
| 2018 | $110.24M | -32.1% |
| 2017 | $162.39M | -36.2% |
| 2016 | $254.44M | - |